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Abstract
Anti-dengue T-cell responses have been implicated in both protection and immunopathology. However, most of the T-cell
studies for dengue include few epitopes, with limited knowledge of their inter-serotype variation and the breadth of their
human leukocyte antigen (HLA) affinity. In order to expand our knowledge of HLA-restricted dengue epitopes, we screened
T-cell responses against 477 overlapping peptides derived from structural and non-structural proteins of the dengue virus
serotype 3 (DENV3) by use of HLA class I and II transgenic mice (TgM): A2, A24, B7, DR2, DR3 and DR4. TgM were inoculated
with peptides pools and the T-cell immunogenic peptides were identified by ELISPOT. Nine HLA class I and 97 HLA class II
novel DENV3 epitopes were identified based on immunogenicity in TgM and their HLA affinity was further confirmed by
binding assays analysis. A subset of these epitopes activated memory T-cells from DENV3 immune volunteers and was also
capable of priming naı¨ve T-cells, ex vivo, from dengue IgG negative individuals. Analysis of inter- and intra-serotype variation
of such an epitope (A02-restricted) allowed us to identify altered peptide ligands not only in DENV3 but also in other DENV
serotypes. These studies also characterized the HLA promiscuity of 23 HLA class II epitopes bearing highly conserved
sequences, six of which could bind to more than 10 different HLA molecules representing a large percentage of the global
population. These epitope data are invaluable to investigate the role of T-cells in dengue immunity/pathogenesis and
vaccine design.
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Introduction
Dengue is a member of the genus Flavivirus with a positive sense,
single stranded RNA genome of,10 kb. The genome encodes for
a polyprotein that is co- and post-translationally cleaved into 10
proteins: three structural (capsid, precursor membrane and
envelope), which constitute the virus particle; and seven non-
structural proteins (NS1, 2a, 2b, 3, 4a, 4b and 5), which are
proteases that cleave the viral polyprotein and contribute to the
formation of the replication complex [1,2,3]. The virus exists in
nature as a complex population of four dengue serotypes (DENV1,
2, 3 and 4), consisting of up to 86% homology of amino acid
sequences between serotypes [4].
DENV infection, transmitted primarily by the Aedes aegypti
mosquito, is a major global health problem in tropical and
subtropical areas [5]. The typical spectrum of the dengue disease
ranges from asymptomatic to a mild form of the disease, dengue
fever (DF). However, a small fraction of the patients develops a
severe form of the disease, characterized by increased vascular
permeability (dengue hemorrhagic fever - DHF) that can lead to
hypovolemic shock (dengue shock syndrome, DSS) and even
death.
The leading theories underlying DHF immunopathology are
based on the observation that sequential infection with different
dengue serotypes leads to greater risk of developing a more severe
form of the disease. The earliest postulated mechanistic theory
proposes that cross-reactive and non-neutralizing antibodies would
form immune complexes with the viruses, that can mediate
enhanced infection of Fcc receptor-expressing cells [6,7].
Several dengue vaccine candidates have been shown to induce
memory T-cell response that can confer protection against dengue
infection [8,9]. The importance of protective cytotoxic T
lymphocyte (CTL) responses in primary dengue infection has
been demonstrated in IFNa/bR knock out mice model [10].
Despite the lack of IFN type I responses in this animal model,
immunization with dengue CTL and T-helper (Th) cell epitopes
has been shown to contribute towards faster clearance of the virus
[10,11]. However, a number of studies have suggested a possible
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involvement of cross-reactive HLA class I T-cells epitopes in
dengue pathogenesis. Memory T-cell clones generated during a
primary infection in response to epitopes from one dengue
serotype, would cross-react with epitope variants presented during
a subsequent infection with a different dengue serotype, to elicit
abnormal responses (cytokine storm) associated with capillary
leakage [12].
Despite the increased acknowledgement that T-cells play a role
in both the pathology of and protection from dengue infection, a
more comprehensive analysis of T-cell activation during dengue
infection is hampered by the small repertoire of known dengue T-
cell epitopes in humans. Most of the known epitopes are associated
with DENV2, and are restricted to a small number of human
leucocyte antigens (HLAs) [9,13,14,15,16,17,18,19]. Reported T-
cell epitopes from DENV3, however, are limited and mostly in
NS3 protein [15,16,18,20,21,22,23,24,25,26,27,28,29,30]. The
search for DENV3 T-cell epitopes has been motivated by the
association of DENV3 with major outbreaks in the Americas and
Southeast Asia, infecting adults and children and causing a wide
spectrum of disease severity [31,32,33,34,35,36,37,38]. Thus, the
search for DENV3 T-cell epitopes is necessary.
We previously showed that T-cell responses elicited either by
attenuated yellow fever vaccine (17DD) or peptide immunization
were similar in terms of epitope repertoire and immune
dominance [39]. We also demonstrated a correlation between
the strength of binding to HLA class I and epitope immunoge-
nicity [39,40]. Based on these studies, we devised an optimized
strategy for identification and characterization of DENV3 T-cell
epitopes by use of overlapping peptide libraries which were
constructed based on protein sequences of DENV3 isolates of our
human cohort [37] followed by in silico and biochemical
characterization of the immunogenic peptides. This strategy was
applied to HLA transgenic mice, an effective animal model to use
for identifying potential epitopes recognized by human T-cells.
The repertoire of epitopes identified in these animal models has
been correlated with those identified in humans [41,42,43], and
thus, the strategy was proven to be an effective platform for
epitope discovery [44].
Recently, IFN a/bR KO mice were backcrossed with different
HLA transgenic mice [17] and used to discover HLA-A02-
restricted T-cell epitopes upon infection with a mice-adapted
DENV2 S221 strain. In the current study, however, we used a
mouse model with functional IFN a/bR and identified T-cell
epitopes of DENV3 Envelope, NS1, NS3 and NS5 proteins by use
of transgenic mice expressing HLA class I (A2, A24 and B7) and II
(DR2, DR3 and DR4) molecules. The affinity of the epitopes to
their specific HLAs was confirmed by binding assays. A subset of
the epitopes identified the presence of activated memory T-cells
from subjects naturally infected with DENV3, and also effectively
primed naı¨ve T-cell clones from dengue IgG negative individuals
(dengue naı¨ve). Additionally, analysis of intra- and inter-serotype
variants was carried out for one HLA class I epitope for
identification of possible altered epitope ligands in other DENV
serotypes. This could facilitate the identification of epitope variants
that could cause aberrant memory T-cell activation.
An effective dengue vaccine needs to provide broad population
coverage and induce immune response against majority variants of
the four dengue serotypes. Therefore it would be desirable for a
dengue vaccine to target the T-cell responses against conserved
amino acid sequences that can be presented by multiple HLAs. In
our previously reported preliminary study, we showed that
epitopes containing highly conserved dengue sequences (pan-
dengue sequences; defined as being present in each of the four
dengue serotypes with an incidence of 80% or more [45]) are
immunogenic in HLA TgM. Herein, we showed that such
sequences can also be quite promiscuous, binding as many as 14
different HLA molecules. The results suggest that T-cell epitopes
containing highly conserved in each of the four dengue serotypes
could be immunogenic in a large percentage of the global
population and, thus, potentially useful for further exploration as a
vaccine target against DENV.
Materials and Methods
Ethics statement
This study was performed in strict accordance to the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
TgM protocol was approved by The Johns Hopkins University
(JHU) Institutional Animal Care & Use Committee (MOO7M78).
Adult subjects with history of dengue infection analyzed in this
study were recruited from a cohort of suspected dengue cases
established in Recife, Pernambuco, Brazil and described by
Cordeiro et al. [37]. All patients provided their written informed
consent to participate and this study was reviewed and approved
by the ethics committee of the Brazilian Ministry of Health
(CONEP: 4909; Process nu 25000.119007/2002-03; CEP: 68/02).
In addition, the Johns Hopkins University Institutional Review
Board reviewed and approved the study (protocol JHM-IRB-3: 03-
08-27-01).
Peptide library
Synthetic peptides covering the full-length Envelope (Env; 95
peptides), NS1 (75), NS3 (150), and NS5 (156) protein sequences of
DENV3 Philippines/H87/1956 isolate (UniProtKB/Swiss-Prot
Accession: P27915; GenPept: AAA99437) were obtained for the
study (Supplementary Table S1). The Env, NS1 and NS3 peptides
were 15-mers, overlapping by 10–11 amino acids (aa), and
synthesized by Schafer-N (Denmark), while the NS5 peptides were
13- to 17-mers, overlapping by 11 to 13 aa, and obtained from
BEI Resources, NIH (Supplementary Table S1). All the 9-mer
peptides used for HLA class I minimal epitope discovery and
analysis of the variants of DENV NS3399–407 were purchased from
Genscript Corporation. All peptides were dissolved in 10% (v/v)
dimethyl sulfoxide (DMSO; Sigma) at 2 mg/mL, aliquoted and
stored at 220uC until use.
Author Summary
Although there is an increased recognition of the role of
T-cells in both dengue pathogenesis and protection,
comprehensive analysis of T-cell activation during dengue
infection is hampered by the small repertoire of known
human dengue T-cell epitopes. Although dengue serotype
3 (DENV3) is responsible for numerous outbreaks world-
wide, most of the known epitopes are from studies of
dengue 2 serotype (DENV2). In this study, we identified
novel DENV3 T-cell epitopes in HLA transgenic mice that
were confirmed by HLA binding assays. A subset of these
epitopes activated memory T-cells from subjects who were
dengue IgG positive and primed naı¨ve T-cells from dengue
IgG negative individuals. Notably, some of HLA class II
epitopes bearing highly conserved regions common to all
four dengue serotypes could bind to multiple HLAs. We
postulate that these highly conserved and HLA promiscu-
ous T-helper epitopes can be important components of a
dengue tetravalent vaccine.
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HLA transgenic mice (TgM)
Murine H-2 class II-deficient, HLA-A02 (A*0201) [46], HLA-
B07 (B*0702) [47], HLA-A24 (A*2402) (Lemonnier et al.
unpublished), HLA-DR2 (DRA1*0101/I-Ea; DRB1*1501/I-Eb)
[48], HLA-DR3 (DRA1*0101; -DRB1*0301) [49,50], and HLA-
DR4 (HLA-DRA1*0101; -DRB1*0401) [51], animals were bred
and maintained in the Johns Hopkins University School of
Medicine Animal Facility. Specific pathogen-free colonies were
maintained in a helicobacter-negative mice facility. HLA expres-
sion of the experimental transgenic mice was evaluated by flow
cytometry (data not shown).
Immunizations protocol
Ten to 15 mice were injected twice, two weeks apart, with a
pool of peptides (1 mg/peptide) emulsed in Titermax gold
(Titermax) or only Titermax gold (negative control) according to
the manufacturer directions. The immunization was performed
through subcutaneous route.
Tissue processing and splenocyte isolation
Two weeks after the last immunization, the mice were sacrificed
and their spleens were aseptically removed and placed into a
disposable sterile petri dish containing 5 mL of RPMI media,
followed by manual dissociation and grinding (pressing tissue
against a sterile 70 mm cell strainer). After washing the strainer
with 15 mL of RPMI media, the splenocytes were transferred into
a 50 mL conical tube and centrifuged 5006g for 5 minutes at
room temperature (RT). Red blood cells with the splenocytes were
lysed by treating the pellets with ammonium-chloride-potassium
(ACK) lysing buffer (3 mL per spleen) for 3 minutes at RT. The
splenocytes were then washed by addition of 20 mL of RPMI
media, centrifuged at 5006g for 5 minutes at 4uC, resuspended,
strained and counted using a Vi-Cell analyzer (Beckman Dickson).
The isolated splenocytes were depleted of murine CD4 (HLA class
I TgM) or CD8 (HLA class II TgM) positive cells by the use of
antibody-coated microbeads and LD columns manufactured by
Miltenyi Biotec following the instructions of the manufacturer.
Mapping of T-cell epitopes using HLA transgenic mice
The cells from immunized and control mice were screened by
IFN-c ELISPOT assays for memory T-cell response against either
the pooled or individual peptides used in the immunization
peptide pool. The strategy for epitope mapping, as depicted on
Figure 1, included a first round of screening of overlapping
peptides arrayed in different matrix pools (Envelope, 10610; NS1,
969; NS3 and NS5, 13612), whereby each peptide is present in
two different pools [52]. This was followed by a deconvolution of
the positive pools. The peptide concentration in both of these steps
was 10 mg/mL. Lastly, the functional avidity of the immunogenic
peptides was assessed by measuring T-cell response against the
peptides at different concentrations (10 mg/mL, 1 mg/mL and
0.1 mg/mL) as previously reported [53].
HLA typing
Low resolution HLA typing for HLA-A, HLA-B, HLA-Cw,
HLA-DR, and HLA-DQ loci was performed using Sequence
Specific Primers amplification methods as described elsewhere
[54].
Plaque reduction neutralization test
The primary virus strains DENV-1 (PE/97-42735), DENV-2
(PE/95-3808), DENV-3 (PE/02-95016) and DENV-4 (IEC)
isolated in Brazil were expanded on African green monkey kidney
cells and used in a standard plaque reduction neutralization test
with the same cell line and heat-inactivated patient sera as
described [55]. Serum samples were used at two-fold dilutions
ranging from 1/20 to 1/2560. The 50% end-point dilution of each
serum, corresponding to the dilution at which 50% of the wells
were completely protected from infection, was determined
according to standard methods. Fifty percent plaque neutralization
titers (PRNT50) were calculated as the highest dilution of Ab
reducing virus plaques by 50%.
Human dengue cohort
Peripheral blood samples were obtained from 5 subjects
enrolled in this cohort who had history of dengue infection with
different virus serotypes, including DENV3, for at least a year,
prior to the blood collection. Demographic, dengue serotype-
specific immunity status and HLA typing information are shown
in supplementary Tables S1 and S2.
Preparation of human PBMC
Blood from the subjects was collected in heparinized tubes (BD
Biosciences) 1 to 3 years year after onset of symptoms. PBMCs
were isolated by gradient density using Ficoll-Paque Plus
according to the instructions of the manufacturer (GE Healthcare).
The cells were then washed once with PBS (Phosphate Buffer
Saline) pH 7.2 and the red cells were lysed with ACK Lysing
buffer (Biosource International, Inc) for 3 minutes at room
temperature (RT). The cells were then centrifuged at 5306g for
5 minutes at 4uC and re-suspended, strained and counted by use
of cell analyzer Vi-Cell XR (Beckman Coulter).
PBMC from HLA-A02 or HLA-B07 positive volunteers were
used to assess the immunogenicity of the HLA-class I epitopes
while HLA-DR2 positive donors were used to assess the
immunogenicity of HLA-class II epitopes. The CD4+ T-cells
and CD8+ T-cells were depleted from the HLA-A02/B07 positive
donors and the HLA-DR2+ donors respectively. Cell depletion
was carried out by magnetic bead cell isolation using Miltenyi
CD4+ and CD8+ microbeads and LD columns (Miltenyi Biotec)
according to the manufacturer manual. Following the cell
depletion step, the remaining cells were suspended at 2.56106
cell/mL and cultured at 37uC, 5% CO2 in RPMI media
containing 8% (v/v) T-cell growth factor (TCGF), 5% (v/v)
autologous plasma. T-cells were activated with individual peptides
at 10 mg/mL. On day 4, the cell cultures were replenished with
TCGF and autologous plasma. On day 8, the cells were harvested
and washed with serum-free media (Gibco) to prepare for
ELISPOT analysis as described below.
ELISPOT assays for IFN-c
ELISPOT assays for IFN-c detection were performed using the
IFN-c ELISPOT set from BD Biosciences, according to the
manufacturer’s instructions. Briefly, the ELISPOT plate (96-well)
was coated with anti-mouse IFN-c at 5 mg/mL and incubated at
4uC overnight. The plate was blocked with RPMI-1640 containing
10% heat-inactivated fetal bovine serum (HyClone), 1% L-
Glutamine (Gibco), 1% penicillin/streptomycin (Gibco) for 2 h at
RT. Peptide pools or individual peptides were then plated in
duplicate. The cells were then added at a range of 5 to 106105 cells/
well. Concanavalin A (Sigma), at 2.5 mg/mL, was used as a positive
control while media was used as a negative control (background).
After an 18 h incubation at 37uC and 5% CO2, the plate was
washed and incubated with biotinylated anti-mouse IFN-c at 2 mg/
mL for 2 h at RT. Streptavidin-HRP 100-fold diluted was then
added and incubated for 1 h at RT. The plate was washed and
reactions were developed with 3-amino-9-ethylcarbazole (AEC)
Characterization of DENV3 T-Cell Epitopes
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Figure 1. Flowchart showing the high-throughput epitope mapping strategy carried out in this study.
doi:10.1371/journal.pntd.0002497.g001
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substrate (BD Biosciences Pharmingen). Spot development was
stopped after 30 min incubation by washing the plate with distilled
water. The plate was dried at RT and the spots were counted with
the Immunospot Series 3B Analyser ELISPOT reader (Cellular
Technologies Ltd) using the program Immunospot software version
3.0 (Cellular Technologies Ltd). The spot average was normalized
and expressed as the number of spot-forming cells (SFC) per 1
million cells.
ELISPOT assays were also used to assess human T-cell
responses using a protocol similar to the above using a human
IFN-c ELISPOT kit (BD Biosciences); phorbol 12-myristate 13-
acetate (PMA; Sigma) at 250 ng/mL and ionomycin (Sigma) at
250 ng/mL were used as a positive assay control. Peptide pools
and individual peptides were considered positive in the ELISPOT
assay when all three criteria described bellow were met:
(i) mean number of spots (peptide pool or individual peptides) minus 2
standard deviation (SD) was greater than the mean number of spots
(background);
(ii) mean number of spots (peptide pool or individual peptides) was greater
than the mean number of spots (background) plus 2SD;
(iii) mean number of spots (peptide pool or individual peptides) minus mean
number of spots (background) was greater than 10 spots per million
cells.
These criteria were used consistently throughout this study.
Generation of human DCs and induction of primary CTL
responses
Monocytes were isolated from peripheral blood of healthy
donors (Central Blood Bank of Pittsburgh, USA) and cultured for
5–7 days in 24-well plates at 56105 cells per well in the presence
of GM-CSF and IL-4 (both 1000 IU/ml). The immature DCs
were then exposed to the following combination of activation
factors for 48 h: rhIL-1b (25 ng/ml), rhTNFa (50 ng/ml), rhIFNa
(1000 IU), Poly IC (20 mg/ml) and IFNc (1000 IU/ml). As
previously described [56], high IL-12 p70 producing type-1
polarized DC (aDC1) were induced
CTL were generated using a protocol similar to what we
previously described [56]. Briefly, CD8+ T-cells were isolated
from the peripheral blood of dengue virus naı¨ve (dengue IgG
negative) HLA-A2+ donors by negative selection using the
EasySep system (Stem Cell Technologies). The T-cells were plated
at 7.56105cells/well in 48 well plates (Falcon, BD Labware) and
sensitized with 9-mer peptide-pulsed autologous aDC1 (7.5e4
cells/well). To mimic their interaction with CD40L-expressing
CD4+ T-helper cells, as a surrogate we added to the cultures c-
irradiated (3000 Rad) J558-CD40L cells (5e4 cells/well) (provided
as a gift from Dr. P Lane, University of Birmingham, Birmingham,
U.K.). From day 4 onwards, rhIL-2 (50 units/ml), rhIL-7 (10 ng/
ml), and rhIL-15 (100 IU/ml) were added to the cultures every 4
days upon media replacement. The cultures were provided one
round of in vitro sensitization at day 14 by adding relevant
peptide-pulsed c2irradiated (3000 Rad) A2+ T2 cells (provided by
Dr. W Storkus, University of Pittsburgh) at target cells to T-cell
responder ratio of 1:5. On day 20, the T-cells were screened for
the presence of antigen specific CTL by IFN-c ELISPOT assay
described previously. Long term CTL lines from ELISPOT
positive cultures were established and maintained under the
described culture conditions with IL-2 concentration being
increased to 500 IU/ml. The cultures were re-sensitized with
peptide pulsed c2irradiated T2 cells every 10 days and used
periodically during the study.
Prediction of HLA class I epitopes and determination of
HLA class II core region interaction
Prediction of HLA class I T-cell epitopes for HLA-A*0201,
HLA-A*2402 and HLA-B*0702 molecules was performed by use
of the ANN (artificial neural network) algorithm based prediction
tool at the Immune Epitope Database (IEDB) and Analysis
Resource (http://tools.immuneepitope.org/analyze/html/mhc_
binding.html). The peptide sequences (13-mer to 17-mer) were
input to the prediction server and prediction was carried out for all
possible lengths (8-mer to 11-mer). Peptide sequences predicted
with IC50 below 500 nM were considered for further analysis.
For determination of HLA class II core region interaction
within the peptides bearing pan-dengue conserved sequences,
stabilization matrix method (SMM), artificial neural network (NN)
and Sturniolo alignment algorithms [57,58,59] were used. The
peptide sequences were input to the IEDB server for identification
of HLA class II epitopes under the IEDB recommended prediction
method. Then, the 9-mer sequence of align core (core region
interaction) for the lowest predicted IC50 was annotated for each
prediction method.
HLA purification and binding assays
Purification of HLA class I (A*2402 and B*0702) and HLA class II
molecules (DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0404,
DRB1*0405, DRB1*0701, DRB1*0802, DRB1*0901, DRB1*1101,
DRB1*1302, DRB1*1501, DRB3*0101, DRB4*0101 and DRB5
*0101) by affinity chromatography and the quantification of peptide
binding based on competitive inhibition assay against binding of a
high affinity radiolabeled standard peptide were performed as detailed
elsewhere [60,61,62,63,64]. Briefly, EBV transformed homozygous
cell lines were used as sources of HLA molecules. A high affinity
radiolabeled peptide (0.1–1 nM) was co-incubated at room temper-
ature or 37C with purified HLA in the presence of a cocktail of
protease inhibitors. Following a two-day incubation, HLA bound
radioactivity was determined by capturing HLA/peptide complexes
on Ab coated Lumitrac 600 plates (Greiner Bio-one, Frickenhausen,
Germany), and measuring bound cpm using the TopCount (Packard
Instrument Co., Meriden, CT) microscintillation counter. The
concentration of peptide yielding 50% inhibition of the binding of
the radiolabeled peptide was calculated. Under the conditions utilized,
where [label],[HLA] and IC50$[HLA], the measured IC50 values
are reasonable approximations of the true Kd values. Each competitor
peptide was tested at six different concentrations covering a 100,000-
fold range, and in three or more independent experiments. As a
positive control, the unlabeled version of the radiolabeled probe was
also tested in each experiment.
Dengue competitive binding assay using HLA-A2:Ig
fusion protein
Binding assay for HLA-A*0201 was performed using HLA-
A2:Ig fusion protein. The labeled peptide (ALMDKVLKV) was
commercially synthesized by GenScript Corporation as a refer-
ence peptide for the binding assay. A fluorescein moiety was
introduced into position P8 of the designed peptide
(ALMDKVLKV). This chemical modification has been previously
shown to not affect the peptide’s affinity for the HLA*A2 binding
pocket [65]. The lyophilized labeled peptide was diluted in 100%
DMF (Dimethylformamide) to a final concentration of 10 mM.
Subsequent dilutions were carried out using 0.5 mg/ml bovine-c-
globulin (BGG) in 16PBS.
Soluble HLA-A2:Ig dimer complexes were obtained from BD
Biosciences. This fusion protein consists of two extracellular
portions of the major histocompatibility complex (MHC) class I
Characterization of DENV3 T-Cell Epitopes
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HLA-A2 domains fused to the variable regions of a mouse IgG1
antibody. Additional b2-microglobulin (Fitzgerald Industries) was
added to the binding assays to retain the fusion protein in a
functional state. Fluorescence polarization was measured by a
SpectraMax M5 reader (Molecular Devices, Sunnyvale CA) using
an excitation wavelength of 485 nM and an emission wavelength
of 530 nM. The competitive binding assays were carried out at
room temperature for an incubation period of 3 days.
Both labeled and unlabeled peptides were added to the reaction
mixture before the HLA-A2:Ig fusion protein, ensuring that both
peptides were presented simultaneously to the HLA molecule. To
avoid peptide photobleaching, the reaction mixture was incubated
within aluminum foil covered microcentrifuge tubes. After the 3
days incubation period, 20 ml of the reaction mixture was loaded
into individual wells of a black, non-binding surface (NBS) 384
well plate (Corning). Controls included only buffer (blank), protein
and pFITC. Each experiment was performed in quadruplicate and
reported as the mean with standard deviation. The reported IC50
values were obtained by fitting the mean of 13 data points to a
four-parameter logistic equation:
Y~minz
max{minð Þ
1z10 log=C50{xð ÞB
where, max indicates the upper plateau of the curve; min, the
lower plateau and B, is the slope factor, which describes the
steepness of the curve transition.
Diversity analysis HLA-A*0201-restricted DENV3
NS3399–407 epitope and variants
NS3 protein sequences of each DENV serotype (696 for
DENV1, 681 DENV2, 585 DENV3, and 71 DENV4; as of Feb.
2009) were collected from the NCBI Entrez Protein Database and
aligned, following the method in Khan et al., (2008) [45]. The
region of each serotype alignment corresponding to the DENV3
NS3399–407 epitope sequence (KLNDWDFVV) was extracted and
analysed for all the peptides that were variant/different to the
epitope sequence by at least one amino acid difference. The
incidence (% occurrence) of the individual variants in each DENV
serotype NS3 alignment was determined. Inter-serotype variant
peptides (DENV1, 2 and 4) with an incidence of 5% or more and
predicted to be a potential epitope of HLA-A*0201 were
synthesized and their binding affinity and immunogenicity
assayed.
Results
Epitope identification in HLA transgenic mice
The immunogenicity of each of the 477 peptides from DENV3
envelope (Env), NS1, NS3 and NS5 proteins (Supplementary
Table S3) were tested in six HLA transgenic mice (TgM) strains
(A02, A24, B07, DR2, DR3 and DR4) using IFN-c ELISPOT as
the initial screening readout (Figure 1). A total of 13 novel peptides
were shown to be immunogenic in HLA class I transgenic mice
(TgM) [A02 (n= 5), A24 (n= 3) and B07 (n= 5)], six of which were
located in Env, three in NS3 and four in NS5 (Table 1). No HLA
class I epitope was found in NS1 protein. A02 and B07 epitopes
were presented in Env, NS3 and NS5, whereas A24 epitopes were
present only in Env. In contrast to HLA class I, a total of 173
peptides were shown to be immunogenic in HLA class II TgM
[DR2 (n= 64), DR3 (n= 50) and DR4 (n= 59) (Supplentary
material S3)], 36 of which were located in Env, 31 in NS1, 48 in
NS3, and 58 in NS5 (Supplementary Table S4).
Binding assays
Affinity of the immunogenic peptides to the respective HLA of
the TgM was confirmed by use of HLA-binding assay. HLA class I
binding groove fits peptides between 8 to 12 amino acid (aa) long
(typically 9 aa). Hence, in silico analysis was first performed to
identify 9-mer(s) within the immunogenic peptides (15-mers to 17-
mers) that were potential binders of the respective HLA of the
TgM. Nine out of the 13 immunogenic peptides encompassed
binding motifs for the HLA they were immunogenic in the animal
studies and, thus, they were selected for peptide synthesis and
binding assay analysis, which further confirmed the affinity of all
tested peptides (Table 1).
Table 1. Identification of DENV3 HLA class I (A02, B07 and A24) T-cell epitopes using HLA transgenic mice, epitope prediction and
binding assays.
Transgenic Mice Peptide Sequence SFC±SD (Functional avidity in mg/mL) Predicted sequence Binding affinity (nM)
A02 Env106–120 GLFGKGSLVTCAKFQ 1160 (10) GLFGKGSLV 2.9
NS3393–407 TEYQKTKLNDWDFVV 2065 (0.1) KLNDWDFVV 110
NS5227–243 IVSSVNMVSRLLLNRFT 44611 (10) None -
NS5312–328 ATGSASSMINGVVKLLT 8168 (1) SMINGVVKL 281
NS5318–334 SMINGVVKLLTKPWDVV 89622 (0.1) SMINGVVKL
KLLTKPWDV
281
619
A24 Env296–310 SYAMCTNTFVLKKEV 14869 (1) SYAMCTNTF 14
Env441–455 AYTALFSGVSWVMKI 1864 (10) None -
Env466–480 LNSKNTSMSFSCIAI 3160 (1) None -
B07 Env221–235 GATTETPTWNRKELL 19262 (10) TPTWNRKEL 2.8
Env226–240 TPTWNRKELLVTFKN 45667 (0.1)
NS3589–603 KKKLRPRWLDARTYS 11565 (1) RPRWLDART 2.1
NS3593–607 RPRWLDARTYSDPLA 13963 (1)
NS5382–398 RTLGRNKRPRLCTREEF 501619 (0.1) RPRLCTREEF 7.1
doi:10.1371/journal.pntd.0002497.t001
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The open topology of the HLA class II groove, fitting longer
peptides than class I, allowed direct use of the immunogenic
peptides (15-mer to 17-mer) for the binding assay, without the
preliminary in silico binding prediction. Binding assay was
performed against the HLA of three class II TgM [DR2
(DRB1*1501), DR3 (DRB1*0301) and DR4 (DRB1*0401)], as
well as eleven additional HLA class II molecules (see methods) for
the analysis of epitope promiscuity. HLA binding affinity was
confirmed for 39 DR2-, 26 DR3- and 47 DR4-specific epitopes,
representing 65%, 53% and 84% of the total positive peptides of
DR2, DR3 and DR4 TgM respectively (Supplementary Table S5).
Furthermore, many of the peptides tested showed affinity to
multiple HLA molecules (supplementary material S1).
HLA class II epitope promiscuity based on
immunogenicity and binding affinity
The number of peptides that elicited T-cell responses in two
HLA class II TgMs ranged from 5 to 6 peptides, whereas only 2
peptides were immunogenic in all three HLAs tested in TgM
(Figure 2A). The majority of the peptides were positive in only one
TgM strain analyzed. However, the binding assay analysis suggests
that these peptides are more promiscuous. The majority of the
class II peptides had binding affinity to more than one HLA. The
number of peptides that had affinity to DR2/DR3, DR2/DR4,
DR3/DR4 and DR2/DR3/DR4 were 9, 18, 6 and 17,
respectively (Figure 2B).
Imunogenicity of the epitopes in human: Epitope
processing and priming analysis in human subjects
TgM and binding affinity assays are useful tools for determi-
nation of HLA affinity of an epitope. However, experimental
validation of the T-cell epitopes in humans is necessary for
accurate interpretation of results. Hence, a subset of the T-cell
epitopes, identified herein by use of TgM with HLA affinity
confirmed by binding assays, was selected for immunogenicity
study in humans by use of PBMC collected from subjects immune
to DENV3 (Supplementary Tables S1 and S2). In addition, DR2
epitopes were selected based on their functional avidity, defined as
the ability to activate CD4 T-cells at concentrations below 0.1 mg/
mL and high affinity to HLA-DR2 molecule (IC50 below 20 nM).
This additional criterion was applied in order to reduce the
number of DR2 peptides to test and also to select only the peptides
with increased likelihood to induce T-cell responses. PBMCs from
A02 (n= 2), B07 (n= 2) and DR2 (n= 3) positive subjects were
either CD4 depleted (A02 and B07) or CD8 depleted (DR2) and
cultured for a week with a peptide pool containing the HLA-
matched epitopes, followed by analysis of T-cell activation by use
of ELISPOT to detect IFN-c secretion. Among the A02 positive
subjects tested, consistent response against peptide NS3399–407 was
observed in all subjects, whereas only one of the two responded
against the peptide NS5318–326 (Figure 3B). No T-cell response was
detected against the peptides Env106–114 and NS5325–333 (Figure 3A
& 3B). All subjects analyzed for B07 epitopes elicited T-cell
response against the peptide NS5389–398 (Figure 3C & 3D).
However, T-cell response against Env226–234 and NS3593–601 was
observed only in one of the two subjects analyzed (Figure 3C). The
peptides Env126–140 and NS185–99 reproducibly activated memory
T-cells on all the subjects analyzed for DR2 epitopes (Figure 4).
On the other hand, the peptides Env231–245, NS169–83 and
NS3357–371 elicited T-cell response in one of the volunteers while
the remaining peptides did not elicit any memory T-cell response
(Figure 4). Therefore, majority of the HLA class I and II T-cell
epitopes analyzed activated memory T-cell response in at least one
individual that had experienced DENV3 infection in the past. This
suggests that the epitopes are naturally processed and presented to
T-cells during DENV3 infection.
In addition to showing that the epitopes identified herein are
recognized by human memory T-cells, we tested if a subset of the
epitopes identified herein could prime naı¨ve T-cells for relevance
in epitope-based vaccine design. CD14 positive monocytes were
isolated from PBMC harvested from blood collected from healthy
donors that were known to be IgG negative for dengue.
Monocytes isolated from either HLA-A02 or HLA-B07 positive
individuals were differentiated into mature dendritic cells and
pulsed with peptide pool containing either A*0201 or B*0702
epitopes, respectively, and co-cultured with autologous lympho-
cytes responders. After 20 days, the in vitro-sensitized T-cells were
harvested and reactivity was assessed by IFN-c ELISPOT using
Figure 2. HLA affinity overview among the epitopes identified. (A) Profile based exclusively on immunogenicity in HLA transgenic mice; (B)
Profile based exclusively on binding assay analysis.
doi:10.1371/journal.pntd.0002497.g002
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target cells (peptide-pulsed autologous monocytes) expressing
either HLA-A*0201 and HLA-B*0702 molecules pulsed with
individual peptides. Among the epitopes analyzed, the peptide
DENV3 NS5389–398 (B*0702-restricted) and NS3399–407 (HLA-
A*0201-restricted) reproducibly primed naı¨ve T-cells (Figures 5
and 6 respectively). Thus, a selected repertoire of epitopes
identified using HLA TgM did not only trigger memory T-cell
response in individuals with history of dengue infection, but also
primed T-cell from dengue naı¨ve subjects.
Analysis of variants of DENV3 NS3399–407 in other DENV
serotypes
Altered peptide ligand is thought to be a mechanism driving
memory T-cells toward an aberrant cytokine response associated
with disease severity. Intra- and inter-serotype variant analysis of
the A02-restricted epitope (DENV3 NS3399–407 - KLNDWDFVV)
were performed to assess the potential of the peptides to act as
altered peptide ligands. The DENV3 NS3399–407 epitope had an
incidence of 63% among all analyzed DENV3 sequences collect-
ed from the NCBI Entrez Protein Database (see Methods
section). The remaining ,37% of the sequences constituted four
intra-serotype variants of the epitope (KLNDWDFVV) with only
one peptide of incidence more than 1% (RLNDWDFVV; ,36%).
In contrast, there were 11 inter-serotype variants, but only four
(DENV1: KNNDWDYVV; DENV2: RTNDWDFVV and
RANDWDFVV; DENV4: KLTDWDFVV) had an incidence of
about 5% or more among all analyzed DENV sequences of each
serotype (Table 2). Subsequently, HLA binding prediction analysis
was performed on the inter-serotype variants to assess the effect of
one or two amino acid substitutions to HLA binding. Variants
predicted to retain the HLA affinity were synthesized and tested in
binding assay experiments. Prediction analysis indicated that only
the DENV2 and DENV4 variants retained the affinity to HLA-
A*0201, which was experimentally confirmed (Table 2). Further,
the DENV2 and DENV4 variants were tested for their ability to
prime naı¨ve T-cells was assessed as described in the Methods.
DENV2 variant failed to prime naı¨ve T-cells, but DENV4 variant
could reproducibly trigger naı¨ve T-cell response in vitro (Figure 6)
and, thus, it could potentially be an altered peptide ligand to the
DENV3 epitope KLNDWDFVV.
Conservation and variability of the epitopes
A vaccine should provide broad HLA coverage for relevance at
the population level. Promiscuous epitopes recognize multiple
HLA molecules and are, thus, candidate epitopes for vaccine
design consideration [66]. Additionally, a vaccine should also
Figure 3. T-cell responses triggered by HLA-A*0201 and HLA-B*0702 epitopes in subjects with history of DENV3 infection. CD4
depleted PBMCs were cultured for a week in presence of peptide pool containing either A*0201 or B*0702 epitopes. The cells were then harvested,
washed and ELISPOT assay for IFN-c detection was performed. (A) and (B) represent the T-cell responses of two different HLA-A*02 positive subjects,
whereas (C) and (D) represent T-cell responses of two different HLA-B*07 positive individuals.
doi:10.1371/journal.pntd.0002497.g003
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target conserved epitopes for broad coverage of viral variants.
Therefore, theoretically an effective dengue vaccine would include
promiscuous HLA epitopes that are highly conserved in each of
the dengue serotypes. Previously, we reported several immuno-
genic, pan-dengue conserved sequences by use of HLA class II
TgM [45]. We provide in Table 3 the list of HLA class II TgM
epitopes that had HLA affinity confirmed by binding assay and
contain at least nine consecutive amino acids that are pan-dengue
conserved sequences. We then compared the ability of these
epitopes to induce T-cell responses in TgM and to bind to multiple
HLAs (among the 14 HLA molecules analyzed). The results show
that peptides containing highly conserved regions are equally
immunogenic (Figure 7A) and can bind to as many HLAs
(Figure 7B) as compared to peptides with non-conserved
sequences. Additionally, we investigated if these immunogenic
conserved dengue sequences were present in the 9-mer core
regions encompassing the major pockets in the groove of HLA-
DR2, -DR3 and -DR4 molecules. In silico analysis was carried out
using SMM, NN and Sturniolo prediction algorithms and the core
regions were annotated and depicted in Supplementary Table S6.
For most of the peptides analyzed, the three prediction methods
consistently showed that pan-dengue conserved sequences directly
interact (either partially or entirely) with anchor motifs in the HLA
molecules, suggesting that these sequences indeed are important
for HLA specificity and affinity and, thus, are suitable for epitope-
based vaccine development.
Discussion
CD4 and CD8 T-cells have been shown to mediate protection
against lethal dengue virus challenges in a mice model [10,11].
However, limited dengue-specific T-cell epitopes have been
reported, specifically for DENV3, a serotype responsible for
several outbreaks worldwide [31,32,33,34,35,36,37,38]. Herein,
we have performed an extensive T-cell epitope mapping and
identified more than 90 novel potential T-cell epitopes for Env,
NS1, NS3 and NS5 proteins of DENV3, by use of TgM expressing
a set of HLA class I and II molecules highly frequent in the
Caucasian population.
Herein we identified 185 immunogenic peptides from the entire
peptide library analyzed, 13 of which were HLA class I-restricted
epitopes, whereas 172 were HLA class II-restricted epitopes. The
number of epitopes found on HLA class II TgM outnumbered the
HLA class I counterpart, which is consistent with other studies
Figure 4. T-cell responses triggered by HLA-DR02 epitopes in subjects with history of DENV3 infection. CD8 depleted PBMCs were
cultured for a week with individual peptides. The cells were then harvested and tested for T-cell activation using ELISPOT for IFN-c as read out. (A), (B)
and (C) represent the T-cell responses of three DR02 positive subjects.
doi:10.1371/journal.pntd.0002497.g004
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using the same TgM animal model and similar immunization
strategies [53,67]. The combination of immunization strategy
(with peptide pool), the difference in topology between HLA class
I and II molecules and the HLA class I epitope process-
ing mechanism [68] might explain the reasons for the paucity
of HLA class I epitopes identified in our study and, thus,
revealing to be a caveat for identification of HLA class I restricted
epitopes.
Binding assay analysis was done in order to confirm the HLA
affinity suggested by TgM immunogenicity data. HLA affinity
correspondence between the two data was observed for 9 HLA
class I and 97 HLA class II epitopes. A schema of DENV3
proteome with the location of each confirmed epitope as well as
those reported in the literature are illustrated in Figure 8. A
number of these epitopes were shown to be quite promiscuous,
binding to as many as 14 HLA class II molecules. Besides HLA
promiscuity improving vaccine population coverage, multiple
HLA binding motifs within a peptide antigen have been shown
to enhance T-cell immunogenicity in humans vaccinated with
attenuated yellow fever 17DD vaccine [69].
A comparison between DR2, DR3, and DR4 TgM immuno-
genicity and binding affinity data reported herein showed that not
all the peptides with binding affinity to the HLA(s) induced an
immune response in the transgenic mice. This is likely related to
how T-cells are activated. In order to trigger T-cell responses there
are two essential steps: (1) the epitope must bind to the HLA
molecule; and (2) the T-cell receptor (TCR) on T-cells must re-
cognize the HLA-epitope complex. Binding affinity only takes into
consideration the step 1, while immunogenicity is more complex,
taking into account both steps. Anything that influences epitope
presentation (e.g. epitope dominance) will affect the T-cell acti-
vation and, consequently, will compromise the step 2. Thus, dis-
crepancies observed between binding affinity and immunogenicity
were most likely due to the fact that some peptides failed to
activate T-cells possibly due to epitope competition and/or
dominance during animal immunization.
We selected a subset of epitopes that HLA affinity and TgM
immunogenicity were corresponding for assessment of their ex vivo
immunogenicity (ability to activate memory T-cells) in individuals
with matched HLA and history of DENV3 infections. These
individuals were enrolled in a dengue cohort established in Recife,
Brazil, and described elsewhere [37]. The peptides NS3399–407 and
NS5318–326 (A02 epitopes); NS5389–398, Env226–234 and NS3593–601
(B07 epitopes); Env126–140, Env231–245, NS169–83, NS185–99 and
NS3357–371 (DR2 epitopes) activated memory T-cells of at least
one of the subjects analyzed, suggesting that these epitopes are
Figure 5. ELISPOT data showing T-cell activation of HLA-B07 positive in dengue IgG negative individuals using dendritic cells
pulsed with DENV3 NS5389–398 epitope.
doi:10.1371/journal.pntd.0002497.g005
Table 2. Inter-serotype variants and corresponding incidence
among reported sequences in NCBI Entrez database, with
binding affinity data to HLA-A*0201 molecule.
Peptide Sequence
Inter-serotype variant
incidence (%) IC50 (nM)
DENV3 KLNDWDFVV - 110
DENV1 KNNDWDYVV 46 ND
DENV2 (1) RTNDWDFVV 26 167
DENV2 (2) RANDWDFVV 20 ND
DENV4 KLTDWDFVV 5 61
The underlined sequences show the amino acid changes in relation to DENV3
sequence. ND: non-determined.
doi:10.1371/journal.pntd.0002497.t002
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naturally processed and presented to T-cells during the course of
dengue infection and, thus, are relevant to humans. However, we
cannot rule out the possibility that the epitopes tested could have
been presented by HLA molecules other than those studied herein
or the memory T-cell clones activated were only cross-reactive to
DENV3. Further studies are needed to determine the HLA
restriction and the specificity of these T-cell clones.
We also analyzed the ability of the epitopes to prime naı¨ve T-
cells. Two selected DENV3 epitopes, NS3399–407 (and its variants
on DENV2 and DENV4 serotypes) and NS5389–398, were
analyzed for their ability to activate naı¨ve T-cells from subjects
either HLA-A02 or HLA-B07 positives who had never been
exposed to dengue virus infection by any serotype (dengue IgG
negative). Naı¨ve T-cells were successfully primed by both DENV3
epitopes (NS3399–407 and NS5389–398) and the NS3399–407 variant
in DENV4, but not by the DENV2 variant. The residues lysine
(K) and leucine (L) at the amino termini of the peptide that are
part of the HLA-A*0201 binding motif (www.syfpeithi.de) seemed
to determine the immunogenicity of the peptides as both residues
were present in the DENV3 NS3 epitope and its DENV4 variant,
but not in the DENV2 variant (Table 2). Notably, DENV3
NS3399–407 -primed CD8 T-cells have been shown to recognize
both DENV2 and DENV4 variants leading to a dysfunctional
T-cell response [70]. Thus, more studies are needed to determine
the role of these altered peptide ligands on disease outcome.
Nonetheless, the data suggests that the epitopes are naturally
processed and can potentially prime naı¨ve T-cells, which is
important for vaccine design.
Our epitope screening strategy revealed HLA class I epitopes
found only in non-conserved regions of the virus proteome. We
analyzed the intra- and inter-serotype variants of the A02-
restricted epitope NS3399–407 (KLNDWDFVV) among the
sequences deposited in the NCBI Entrez Protein Database [45]
to assess for the possibility of altered peptide ligands within
DENV3 and between the serotypes. Based on the analysis, an
intra-serotype variant (RLNDWDFVV) and four inter-serotype
variants were identified (Table 2). In silico analysis showed that all,
but DENV1 variant had HLA-A*0201 binding motif, and, thus,
capable of potentially acting as an altered peptide ligand, leading
to aberrant memory T-cell responses.
A study by Hertz et al [71] using targeting efficiency analysis of
different HLA class I molecules has shown that HLA molecules
preferentially target conserved regions on the proteome of
different viruses [71]. This was thought to be the case on DENV
as well [12]. Nevertheless, virus belonging to Flaviviridae family,
such as DENV, are exception to this rule, since there is an
increased preference of HLA molecules to bind non-conserved
regions among the different virus serotypes [71]. However, the
authors found an association between preferential HLA targeting
to conserved regions and protection against dengue severity caused
by DENV2 [71]. Hence, it seems that targeting conserved
sequences is desirable not only in terms of achieving a broad
and efficient pan-dengue immune responses, but also to protect
against disease severity. In contrast to the HLA class I, where we
did not find conserved immunogenic regions, we identified 23
HLA class II immunogenic peptides that contained sequences
highly conserved in each of the four dengue serotypes (pan-dengue
conserved sequences) [45]. In TgM model, these conserved
peptides were as immunogenic (among DR2, DR3 and DR4)
and bound to as many HLA molecules as the peptides containing
non-conserved sequences. Notably, these sequences are predicted
to actively interact with the major pockets in the groove of HLA-
DR2, -DR3 and -DR4 molecules, thus, defining the importance of
these pan-dengue conserved sequences for the affinity and
specificity of the epitopes identified. Moreover, some of the
epitopes bearing pan-dengue conserved sequences could bind as
many as 14 different HLA molecules, suggesting that these
immunogenic conserved sequences could trigger T-cell responses
in a vast number of people. However, it is important to highlight
that these immunogenic and HLA promiscuous peptides are not
optimum epitopes, thus, additional analysis are needed in order to
identify the exact sequences responsible for HLA affinity and
ultimately T-cell activation. The importance of these epitopes in
preventing dengue infection and disease severity as well as
population coverage also needs to be further addressed.
Currently there are as many as 15 reported human T-cell
epitopes for DENV3 in the literature (Table 4; Figure 8; as of
December 2012). Among these, the DR2-restricted epitope
NS3348–362 (GNEWITDFVGKTVWF) reported by Mangada &
Rothman [25] using a cohort of individuals immunized against
Figure 6. ELISPOT data showing T-cell activation of HLA-A02 positive in dengue IgG negative individuals using dendritic cells
pulsed with NS3399–407 epitope on homologous region of DENV2, DENV3 and DENV4 viruses.
doi:10.1371/journal.pntd.0002497.g006
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DENV3 virus correlated with four overlapping DENV3 DR2
TgM epitopes identified herein, covering a larger region (NS3345–
370). Two of the four overlapping epitopes (NS3349–363 and
NS3357–370) had the specificity for DR2 molecule confirmed by
binding assay. Thus, there are possible multiple overlapping
epitope in the region described by Mangada & Rothman. Notably,
the peptide NS3357–370 (GKTVWFVPSIKAGND), which over-
lapped 6 amino acids with the epitope reported by Mangada &
Rothman [25], was observed to bind to DR2 with even greater
affinity and elicit memory T-cell response at a lower concentra-
tion. Additionally, we confirmed the HLA affinity of some of
the previously reported epitopes. For instance, we identified
a potential DR2 (EEMFKKRNLTIMDLH) and a DR4
(KKRNLTIMDLHPGSG) epitope overlapping the NS3187–201
(RNLTIMDLHPGSGKT) with no reported HLA affinity; simi-
larly, a B07 (RPRWLDA) epitope within the NS3585–599
(KEGEKKKLRPRWLDA) [25]. Recently, Weiskopf et al [17]
reported DENV2 T-cell epitopes using IFN a/bR KO HLA
transgenic mice, an animal model that supports dengue replication
and also expresses HLA-A*0201, HLA-B*0702, among other
HLAs. In their study, the authors used DENV2 predicted epitopes
for splenocyte challenge and a mouse-adapted DENV2 strain
for immunization, and among the epitopes identified were five
with identity greater than 89% in DENV3 (identity not observed
for other serotypes). Among these were three HLA-B*0702
epitopes (NS3205–213: LPAIVREAI; NS3223–232: APTRVVAAEM;
Table 3. List of the most conserved DENV3 peptides for which immunogenicity in HLA-DR02, -DR03 and -DR04 transgenic mice
was supported by binding affinity analysis to the respective HLA.
Peptide Sequence Transgenic mice HLA class II binders
DR2 DR3 DR4
NS1225–239 WPKSHTLWSNGVLES - 129+3 - DRB1*0301, DRB1*0401, DRB1*1302, DRB3*0101
NS1229–243 HTLWSNGVLESDMII - 205+12 214+15 DRB1*0301, DRB1*0401, DRB3*0101
NS1261–275 HTQTAGPWHLGKLEL - 337+0 - DRB1*0301, DRB4*0101
NS1293–307 TRGPSLRTTTVSGKL - - 87+41 DRB1*0301, DRB1*0401, DRB1*0701, DRB4*0101
NS3185–199 KKRNLTIMDLHPGSG - - 39+13 DRB1*0101, DR, B1*0301, DRB1*0401, DRB1*0405, DRB1*0802, DRB1*1101,
DRB4*0101, DRB5*0101
NS3293–307 ASIAARGYISTRVGM 27+4 - - DRB1*0101, DRB1*0401, DRB1*0405, DRB1*0701, DRB1*0901, DRB1*1101,
DRB1*1302, DRB1*1501, DRB5*0101
NS3297–311 ARGYISTRVGMGEAA 61+6 - - DRB1*0101, DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0701, DRB1*1101,
DRB1*1501
NS3309–323 EAAAIFMTATPPGTA - - 354+40 DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0701,
DRB1*0802, DRB1*0901, DRB1*1101, DRB1*1501, DRB4*0101
NS3313–327 IFMTATPPGTADAFP - - 46+11 DRB1*0101, DRB1*0401, DRB1*0701, DRB1*0802, DRB4*0101
NS3357–371 GKTVWFVPSIKAGND 406+130 - - DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0701,
DRB1*0802, DRB1*0901, DRB1*1101, DRB1*1302, DRB1*1501, DRB3*0101,
DRB4*0101, DRB5*0101
NS3381–395 KKVIQLSRKTFDTEY - 23+1 - DRB1*0101, DRB1*0301, DRB1*0901, DRB1*1101, DRB3*0101, DRB4*0101
NS3405–419 FVVTTDISEMGANFK - - 482+27 DRB1*0301, DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0802, DRB5*0101
NS3409–423 TDISEMGANFKADRV - 114+17 - DRB1*0301, DRB3*0101, DRB5*0101
NS5295–311 DENPYKTWAYHGSYEVK 126+10 - - DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0701,
DRB1*0901, DRB1*1501, DRB3*0101
NS5301–316 TWAYHGSYEVKATGSA 161+20 - 19+0 DRB1*0101, DRB1*0401, DRB1*0404, DRB1*0701, DRB1*0901, DRB1*1101,
DRB1*1501, DRB3*0101
NS5336–352 MVTQMAMTDTTPFGQQR - - 28+0 DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0701,
DRB1*0802, DRB1*0901, DRB1*1302, DRB3*0101, DRB4*0101
NS5447–463 GSCVYNMMGKREKKLGE - - 16+5 DRB1*0101, DRB1*0401, DRB1*0404, DRB1*0802, DRB1*1101, DRB5*0101
NS5501–517 NSYSGVEGEGLHKLGYI - - 50+10 DRB1*0101, DRB1*0401, DRB1*0701, DRB1*0802, DRB1*0901
NS5523–539 KIPGGAMYADDTAGWDT - - 44+15 DRB1*0101, DRB1*0301, DRB1*0401, DRB1*1101, DRB3*0101, DRB4*0101
NS5564–580 ANAIFKLTYQNKVVKVQ 849+8 - - DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*0901, DRB1*1101,
DRB1*1302, DRB1*1501, DRB3*0101, DRB4*0101, DRB5*0101
NS5588–604 VMDIISRKDQRGSGQVG - 87+7 - DRB1*0301, DRB1*1101
NS5652–668 VERLKRMAISGDDCVVK - 255+22 - DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0701,
DRB1*1101, DRB1*1302, DRB1*1501, DRB3*0101, DRB4*0101, DRB5*0101
NS5765–779 MYFHRRDLRLASNAI 75+16 - 531+10 DRB1*0101, DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0701, DRB1*0802,
DRB1*0901, DRB1*1101, DRB1*1302, DRB1*1501, DRB3*0101, DRB4*0101,
DRB5*0101
A representative ELISPOT data is shown along with the minimum peptide concentration that activated memory T-cells (functional avidity) is included. In addition, IC50
(nM) for HLA-DR02, -DR03 and -DR04 as well as the number of additional potential HLA binders (as many as 11) are also shown. Binding affinity is characterized by IC50
below 1000 nM (in bold).
Pan-dengue conserved sequences are shown underlined.
doi:10.1371/journal.pntd.0002497.t003
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NS3276–283: VPNYNLIIM), however, none was positive in our
study with DENV3 involving TgM. This could be because of the
amino acid differences between the serotypes, however the
increased virus replication within the animal model used might
have contributed to the increased breadth and magnitude of T-cell
response. Additionally, other factors might concomitantly facilitate
the T-cell responses in the IFN a/bR KO HLA transgenic mice,
such as increased antigen availability.
The use of HLA TgM has been shown to be useful tool for the
identification of potential T-cell epitopes, although a validation
step is required [44]. Several studies have shown correlation
between epitopes identified in HLA TgM and humans [42,43,53].
Herein, we have identified a vast repertoire of potential DENV3
T-cell epitopes by use of TgM, with HLA affinity validated for
many by use of binding assay, and immunogenicity confirmed for
a subset in HLA-matched subjects with history of dengue
Figure 8. DENV3 polyprotein schema showing the localization of potential T-cell epitopes identified in this study as well as the
pan-dengue conserved regions (CR) and the list of DENV3 T-cell epitopes reported in the literature.
doi:10.1371/journal.pntd.0002497.g008
Figure 7. Immunogenicity and binding affinity capability of peptides containing non-conserved and pan-dengue conserved
sequences. The percentage of peptides containing non-conserved and pan-dengue conserved sequences was calculated based on their ability to
(A) induce T-cell responses in HLA class II transgenic mice (DR2, DR3 and DR4); or (B) to bind to 14 different HLA molecules.
doi:10.1371/journal.pntd.0002497.g007
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infection. The analysis of intra- and inter-serotype variants
performed is important to identify and understand the role of
altered peptide ligands and T-cell activation in the context of disease
severity caused by DENV and on the other hand population
coverage. Notably, a more extensive human validation study is
currently underway employing the same peptide library used
herein. The data to date reveal that twenty-seven (27) of the TgM
immunogenic peptides (considering only Envelope, NS1 and NS3;
data not shown) are also immune-prevalent (recognized by at least
10% of the subjects tested) in a human cohort of subjects naturally
exposed to DENV3 (Souza et al., manuscript in preparation).
The most advanced dengue vaccine candidates in clinical trials
include the Walter Reed Army Institute of Research-GlaxoSmith-
Kline (WRAIR-GSK) new live attenuated virus vaccine that are
in phase II [72] and the live chimeric virus vaccines, from
Sanofi Pasteur (ChimeriVax), currently in phase III [73]. The
WRAIR-GSK vaccine can induce immune responses against
dengue structural and non-structural viral proteins, while
ChimeriVax induces responses to dengue prM and Env proteins
and yellow fever non-structural proteins. The ability of these
vaccines to induce T-cell responses has been reported [74,75,76].
The complete T-cell repertoires of these vaccines are not known,
but they can potentially induce T-cell responses to both conserved
and non-conserved epitopes. Herein we report highly conserved,
HLA promiscuous dengue T-cell epitopes (mostly found in the
non-structural proteins of the virus) that are capable of inducing
T-cell responses against the majority of dengue variants of each of
the four serotypes and applicable to human population. We
postulate that it would be possible to engineer a dengue vaccine
that could target specifically the conserved T-cell epitopes. This
may be addressed by priming the immune system with highly
conserved, HLA promiscuous T-cell epitopes concomitantly with
Table 4. List of DENV3 epitopes along with HLA affinity (if known) described in the literature and comparison with the
immunogenicity and binding affinity of the peptides tested in this study.
Peptide Tested DENV3 Epitopes Reported
Position Sequence TGM/Binding assay Protein (Sequence)/HLA affinity References
Env206–220
Env211–225
VHRQWFFDLPLPWTS
FFDLPLPWTSGATTE
Negative/ND
Negative/ND
Env211–219 (FFDLPLPWT)/A*2 [20]
NS3129–143
NS3133–147
DFKPGTSGSPIINRE
GTSGSPIINREGKVV
Negative/ND
Negative/ND
NS3133–142 (GTSGSPIINR;GTSGSPIINRE)/A*11, A*1101 [15,21,27]
NS3137–151
NS3141–155
NS3145–159
SPIINREGKVVGLYG
NREGKVVGLYGNGVV
KVVGLYGNGVVTKNG
DR3/DR2,DR3
Negative/ND
Negative/ND
NS3141–155 (NREGKVVGLYGNGVV)/DRB1*1501 [25]
NS3181–195
NS3185–199
NS3189–203
NS3193–207
EEMFKKRNLTIMDLH
KKRNLTIMDLHPGSG
LTIMDLHPGSGKTRK
DLHPGSGKTRKYLPA
DR2/DR2
DR4/DR4
Negative/ND
Negative/ND
NS3187–201 (RNLTIMDLHPGSGKT) [25]
NS3197–211
NS3201–215
GSGKTRKYLPAIVRE
TRKYLPAIVREAIKR
Negative/ND
DR3, DR4/DR4
NS3202–211 (RKYLPAIVRE)/DRB1*15 [28]
NS3221–235
NS3225–239
NS3229–243
ILAPTRVVAAEMEEA
TRVVAAEMEEALKGL
AAEMEEALKGLPIRY
Negative/ND
Negative/ND
Negative/ND
NS3224–238 (PTRVVAAEMEEAMKG; TRVVAAEMEEA)/DRB1*15;
DRB1*1501
[24,25]
NS3237–251
NS3241–255
KGLPIRYQTTATKSE
IRYQTTATKSEHTGR
DR4/DR2, DR4
DR4/DR4
NS3241–249 (IRYQTTATK)/DRB1*15 [28]
NS3249–263
NS3253–267
NS3257–271
KSEHTGREIVDLMCH
TGREIVDLMCHATFT
IVDLMCHATFTMRLL
Negative/ND
Negative/ND
Negative/ND
NS3254–266 (HTGREIVDLMCHATE; EIVDLMCHAT;VDLMCHATFT)/
DPw2
[23,25,26]
NS3345–359
NS3349–363
NS3353–367
NS3357–370
WNSGNEWITDFAGKT
NEWITDFAGKTVWFV
TDFAGKTVWFVPSIK
GKTVWFVPSIKAGND
DR2*/Negative
DR2/DR2
DR2*/Negative
DR2/DR2
NS3348–362 (GNEWITDFVGKTVWF)/DRB1*1501 [25]
NS3497–511
NS3501–515
DNINTPEGIIPALFE
TPEGIIPALFEPERE
Negative/ND
Negative/ND
NS3501–509 (TPEGIIPAL)/B*35 [29,74]
NS3521–535
NS3525–539
NS3529–543
DGEYRLKGESRKTFV
RLKGESRKTFVELMR
ESRKTFVELMRRGDL
Negative/ND
Negative/ND
Negative/ND
NS3528–535 (GESRKTFVE)/B*07; NS3528–536 (GESRKTFVEL)/B*60 [18,27]
NS3553–547
NS3557–571
SEGIKYTDRKWCFDG
KYTDRKWCFDGERNN
Negative/ND
Negative/ND
NS3557–565 (KYTDRKWCF)/A*24 [16]
NS3577–591
NS3581–595
NS3585–599
NS3589–603
NS3593–607
NMDVEIWTKEGEKKK
EIWTKEGEKKKLRPR
KEGEKKKLRPRWLDA
KKKLRPRWLDARTYS
RPRWLDARTYSDPLA
Negative/ND
Negative/ND
Negative/ND
B07/B07
B07/B07
NS3585–599 (KEGEKKKLRPRWLDA) [25]
NS5318–334
NS5324–340
NS5330–346
SMINGVVKLLTKPWDVV
VKLLTKPWDVVPMVTQM
PWDVVPMVTQMAMTDTT
A02/A02
Negative/ND
DR4/DR4
NS5329–337 (KPWDVVPTV) [22]
The sequences in bold represent the epitopes previously identified within the peptides used in this study. ND: non-determined.
doi:10.1371/journal.pntd.0002497.t004
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dengue prM/Env proteins. This may not only help to produce
high affinity neutralizing antibodies, but also would expand T-cell
clones specific for highly conserved dengue T-cell epitopes. These
T-cells would be effectively activated after virus exposure in the field
to produce cytokines (e.g. IFN-c) associated with disease protection.
Further studies are needed to identify the cytokine repertoire that
such epitopes may induce and understand their role in dengue
protection/pathogenesis, as well as establish proper epitope delivery
for efficient antigen presentation and T-cell activation. The data
reported herein are valuable resource for further studies investigat-
ing the role of T-cells in dengue protection/immunopathogenesis
and design of tetravalent dengue vaccine.
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